Tolvaptan

Catalog No.S2593 Synonyms: OPC-41061

For research use only.

Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.

Tolvaptan Chemical Structure

CAS No. 150683-30-0

Selleck's Tolvaptan has been cited by 4 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Vasopressin Receptor Inhibitors

Biological Activity

Description Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.
Targets
vasopressin receptor 2 [4]
3 nM
In vitro

Tolvaptan blocks the binding of [(3)H]AVP to human V(2) receptors with 29-fold greater selectivity than that for V(1a) receptors, and showed no inhibition of V(1b) receptors. Tolvaptan inhibits not only the binding of [(3)H]AVP but also the AVP-induced production of cyclic AMP in human V(2)-receptor-expressing HeLa cells. Tolvaptan shows marked aquaresis in healthy and diseased animals. [1] Tolvaptan causes a concentration-dependent inhibition of arginine vasopressin-induced cAMP production with an apparent IC(50) of 0.1 nM in autosomal dominant polycystic kidney disease (ADPKD) cells. Tolvaptan inhibits AVP-induced ERK signaling and cell proliferation. Tolvaptan inhibits AVP-induced Cl(-) secretion and decreases in vitro cyst growth of ADPKD cells cultured within a three-dimensional collagen matrix. [2]

In vivo Tolvaptan improves hyponatremia, resulting in the prevention of death, and improves organ water retention in rat models with acute and chronic hyponatremia. Tolvaptan reduces cardiac preload without unfavorable effects on renal functions, systemic hemodynamics, or circulating neurohormones in dogs with heart failure (HF). Tolvaptan shows a decrease in kidney weight as well as in cyst and fibrosis volume in animal models of human polycystic kidney disease (PKD). [1] Tolvaptan markedly elevates electrolyte-free water clearance (E-CH(2)O) or aquaresis to a positive value and increases urinary Arginine vasopressin (AVP) excretion in rats with heart failure. [3]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 89 mg/mL
(198.24 mM)
Ethanol 6 mg/mL
(13.36 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 448.94
Formula

C26H25ClN2O3

CAS No. 150683-30-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04182958 Completed Drug: (14C)-OPC-61815 Healthy Adult Male Otsuka Pharmaceutical Co. Ltd. November 25 2019 Phase 1
NCT02994394 Completed Drug: OPC-41061 Healthy Adult Male Otsuka Pharmaceutical Co. Ltd. January 6 2017 Phase 1
NCT02729662 Active not recruiting Drug: Tolvaptan Autosomal Dominant Polycystic Kidney Disease Kyorin University October 1 2016 Not Applicable
NCT02020278 Terminated Drug: Tolvaptan Hyponatremia Otsuka Pharmaceutical Development & Commercialization Inc.|Syneos Health April 22 2016 Phase 3

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Tolvaptan | Tolvaptan ic50 | Tolvaptan price | Tolvaptan cost | Tolvaptan solubility dmso | Tolvaptan purchase | Tolvaptan manufacturer | Tolvaptan research buy | Tolvaptan order | Tolvaptan mouse | Tolvaptan chemical structure | Tolvaptan mw | Tolvaptan molecular weight | Tolvaptan datasheet | Tolvaptan supplier | Tolvaptan in vitro | Tolvaptan cell line | Tolvaptan concentration | Tolvaptan nmr